Abstract
There is currently no reliable and easily applicable diagnostic marker for Parkinson’s disease (PD). The aims of the present study were to compare the expression profiles of the microRNA29 family (miR-29s) in blood serum from patients with PD with healthy controls and to clarify whether the expression of miR-29s is correlated with disease severity, duration or L-dopa therapy and whether expression depends on the gender and age of patients. The levels of blood serum miR-29s in 80 patients with PD and 80 unaffected controls were assessed by reverse transcription-quantitative real-time PCR. The PCR products were confirmed by cloning and sequencing. Additionally, the expression of miR-7 in the blood serum from PD patients and control subjects was assessed. Serum miR-29 levels were significantly downregulated in PD patients compared to healthy controls. The serum miR-29 levels in female PD patients were markedly higher than in male PD patients. The expression of serum miR-29a and miR-29c expression tended to decrease with disease severity. Moreover, we found that serum miR-7 levels did not differ between PD patients and control subjects. Therefore, the reduction of serum miR-29 levels, particularly miR-29a and miR-29c, warrants further investigation of its potential serving as biomarkers for PD.
Highlights
Parkinson’s disease (PD), which is the second most common neurodegenerative disease after Alzheimer’s disease (AD), affects up to 1% of people over the age of 601, 2
Blood serum miR-29s levels are significantly reduced in PD patients. miR-29b-1 and miR-29b-2 have identical mature sequences, while miR-29a and miR-29c differ by one nucleotide (Fig. 1A)
PD patients ranged from early to advanced PD (Hoehn & Yahr stage 1 to 3), and their ages were comparable across groups. quantitative real-time PCR (qRT-PCR) analysis was performed to examine the expression of blood serum miR-29s
Summary
Parkinson’s disease (PD), which is the second most common neurodegenerative disease after Alzheimer’s disease (AD), affects up to 1% of people over the age of 601, 2. The roles of miR-29s in PD remain unclear, and only a few studies have examined the expression of blood miR-29s in PD patients using microarray and quantitative real-time PCR (qRT-PCR)[22,23,24,25]. In cellular and animal PD models, it has been found that dysregulation of some PD-related genes is attributable to the alteration in miRNAs. in cellular and animal PD models, it has been found that dysregulation of some PD-related genes is attributable to the alteration in miRNAs Among such particular miRNAs, miR-7, which is an evolutionarily conserved miRNA that represses the expression of α-synuclein, is associated with PD pathophysiology[26, 27] and is downregulated in serum samples of PD patients[27]. All samples were used to detect the expression levels of miR-7
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
